Literature DB >> 9822917

Recent advances in the histopathology and molecular pathology of carcinoma of the endometrium.

J L Burton1, M Wells.   

Abstract

Endometrial carcinoma is the commonest malignancy of the female genital tract. The pathogenesis is complex and at least three pathogenetic subtypes exist with different prognostic implications. The molecular events involved remain poorly defined but several genes are involved and mutations of tp53, WAF1/CIP1, PTEN, bcl-2 and c-erbB-2 have been implicated. Although care is needed in interpreting the results, the majority of these mutations can be detected immunohistochemically and therefore have the potential to aid the pathologist and surgeon in assessing the prognosis of a tumour. However, for the time being, no molecular marker is as valuable in determining prognosis as conventional parameters such as tumour type, grade and vascular space involvement.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9822917     DOI: 10.1046/j.1365-2559.1998.00560.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  10 in total

1.  Genetic imbalances in precursor lesions of endometrial cancer detected by comparative genomic hybridization.

Authors:  M Kiechle; M Hinrichs; A Jacobsen; J Lüttges; J Pfisterer; F Kommoss; N Arnold
Journal:  Am J Pathol       Date:  2000-06       Impact factor: 4.307

Review 2.  What we could do now: molecular pathology of gynaecological cancer.

Authors:  C S Herrington
Journal:  Mol Pathol       Date:  2001-08

Review 3.  The effect of phytoestrogens on the female genital tract.

Authors:  J L Burton; M Wells
Journal:  J Clin Pathol       Date:  2002-06       Impact factor: 3.411

4.  Poor prognosis of uterine serous carcinoma compared with grade 3 endometrioid carcinoma in early stage patients.

Authors:  Ji Young Park; Joo-Hyun Nam; Young-Tak Kim; Yong-Man Kim; Jong-Hyeok Kim; Dae-Yeon Kim; Insuk Sohn; Shin-Wha Lee; Chang Ohk Sung; Kyu-Rae Kim
Journal:  Virchows Arch       Date:  2013-02-17       Impact factor: 4.064

5.  Does high-grade endometrioid carcinoma (grade 3 FIGO) belong to type I or type II endometrial cancer? A clinical-pathological and immunohistochemical study.

Authors:  Gian Franco Zannoni; Valerio Gaetano Vellone; Vincenzo Arena; Maria Grazia Prisco; Giovanni Scambia; Arnaldo Carbone; Daniela Gallo
Journal:  Virchows Arch       Date:  2010-06-15       Impact factor: 4.064

6.  P53 and BCL-2 as prognostic markers in endometrial carcinoma.

Authors:  Márcia L M Appel; Maria I Edelweiss; James Fleck; Luis F Rivero; Waldemar A Rivoire; Heleusa I Mônego; Ricardo Dos Reis
Journal:  Pathol Oncol Res       Date:  2008-04-09       Impact factor: 3.201

7.  Porcine endometrial 3D co-culture: Morphological changes in 3D endometrium tissues according to hormonal changes.

Authors:  Sang-Hwan Kim; Yong-Su Park; Da-Hye Shin; Jeong-Chan Moon; Min-Gee Oh; Jong-Taek Yoon
Journal:  Histol Histopathol       Date:  2021-04-08       Impact factor: 2.303

8.  HERG potassium channels are more frequently expressed in human endometrial cancer as compared to non-cancerous endometrium.

Authors:  A Cherubini; G L Taddei; O Crociani; M Paglierani; A M Buccoliero; L Fontana; I Noci; P Borri; E Borrani; M Giachi; A Becchetti; B Rosati; E Wanke; M Olivotto; A Arcangeli
Journal:  Br J Cancer       Date:  2000-12       Impact factor: 7.640

9.  The relationship of cerb B 2 expression with estrogen receptor and progesterone receptor and prognostic parameters in endometrial carcinomas.

Authors:  Aylin Ege Gul; Sevinc Hallac Keser; Nagehan Ozdemir Barisik; Nilufer Onak Kandemir; Caglar Cakir; Sibel Sensu; Nimet Karadayi
Journal:  Diagn Pathol       Date:  2010-02-18       Impact factor: 2.644

10.  Gonadotropin releasing hormone analogue (GnRHa) alters the expression and activation of Smad in human endometrial epithelial and stromal cells.

Authors:  Xiaoping Luo; Jingxia Xu; Nasser Chegini
Journal:  Reprod Biol Endocrinol       Date:  2003-12-16       Impact factor: 5.211

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.